NephrosNEPH +1.52%63 OCF Margin % is -32.06% as of Mar. 2026. GuruFocus rates NEPH with a GF Score™ of 63/100 and a GF Value™ of $2.87 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Nephros ranks worse than 63.8% on this metric.
The historical rank and industry rank for Nephros's OCF Margin % or its related term are showing as below:
NEPH'
s OCF Margin % Range Over the Past 10 Years
Min: -91.03 Med: -17.95 Max: 8.76
Current: -1.82
During the past 13 years, the highest OCF Margin % of Nephros was 8.76%. The lowest was -91.03%. And the median was -17.95%.
NEPH's OCF Margin % is ranked worse than 63.8% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 5.86
vs NEPH: -1.82
Nephros OCF Margin % Related Terms
Nephros OCF Margin % Historical Data
* Premium members only.
The historical data trend for Nephros's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Nephros's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nephros OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nephros's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Nephros's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nephros (NEPH) has a OCF Margin % of -32.06% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Nephros and its competitors. According to the industry distribution chart, Nephros ranks #520 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 63.8%.
Is Nephros' OCF Margin % too high?
Nephros' current OCF Margin % is -32.06%. Based on the distribution chart, Nephros ranks #520 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nephros has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nephros' OCF Margin % compare to MLSS and HBIO?
According to the Medical Devices & Instruments industry distribution chart, Nephros ranks #520 out of 815 companies for OCF Margin %. This places Nephros in the lower half of its industry. The industry median OCF Margin % is 5.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Nephros and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nephros's current OCF Margin % is -32.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nephros stock overvalued right now?
Based on GuruFocus' analysis, Nephros (NEPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.87, compared to a current price of $3.35 — trading 16.7% above its estimated fair value. The current OCF Margin % is -32.06%. Nephros' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Nephros (NEPH), the current OCF Margin % is -32.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nephros (NEPH) Overvalued in 2026?
Based on GuruFocus' analysis, Nephros stock appears to be overvalued.
The current stock price of $3.35 is trading 16.7% above its estimated GF Value™ of $2.87.
GuruFocus considers Nephros to be Modestly Overvalued.
Key valuation signals for NEPH:
OCF Margin %: -32.06%
GF Value™: $2.87 vs. price of $3.35 (16.7% above fair value)
No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
63GF Score
Get the complete analysis for NEPH
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEPH has been successfully added to your 
